

# AASLD - TASL CONNECT REGIONAL MEETING

March 15-16, 2019 SWISSOTEL THE BOSPHORUS



İSTANBUL, TURKEY

## March 15, 2019

### [Welcome and Introduction](#)

### Session 1 Hepatitis B Virus

#### [AASLD Guidelines](#)

W. Ray Kim

#### [Debrief from 2018 TLM](#)

Jordan Feld

#### [Translating AASLD data to local practice](#)

Bülent Değertekin

#### [New Therapeutic Perspectives of HBV: When to stop antiviral therapy?](#)

George Papatheodoridis

### Session 2 Hepatitis Delta Virus

#### [Debrief from 2018 TLM](#)

Jordan Feld

#### [Translating AASLD data to local practice](#)

Cihan Yurdaydin

#### [HBV and HDV Case Presentations, Q&A and Panel Discussion](#)

Sevda Agayeva, Suna Yapalı, Ediz Tütüncü

### Session 3 Lunch Symposium 1 - Karaciğere Adanmış Bir Hayat – Gilead

#### [New era in HBV treatment with TAF](#)

Selim Gürel

<a href="#">Today's NASH</a>	Salvador Augustin
<b>Session 4 Cirrhosis and Liver Transplantation</b>	
<a href="#">AASLD Guidelines</a>	Patrick Kamath
<a href="#">Debrief from 2018 TLM</a>	W. Ray Kim
<a href="#">Translating AASLD data to local practice</a>	Zeki Karasu
<a href="#">Surgical innovations in LT</a>	Julie Heimbach
<a href="#">Acute on chronic liver failure</a>	Patrick Kamath
<a href="#">Cirrhosis and Liver Transplantation Case Presentations, Q&amp;A and Panel Discussion</a>	İlker Turan, Mesut Akarsu, Murat Akyıldız
<b>Session Y Rising Star Symposium</b>	
<a href="#">Opening</a>	W. Ray Kim
<a href="#">Best Practice in Getting Your Work Published</a>	Paul Kwo
<a href="#">Best Practice in Scholarly Presentations</a>	Patrick Kamath
<a href="#">Oral Presentations - I</a>	
<a href="#">Best Practice in Conducting Research in a Resource-limited Setting</a>	Jasmohan Bajaj
<a href="#">Opportunities for training in the US</a>	Ahmet Gurakar
<a href="#">Oral Presentations - II</a>	
<b>March 16, 2019</b>	
<b>Session 5 Hepatitis C Virus</b>	
<a href="#">AASLD Guidelines</a>	Paul Kwo
<a href="#">Debrief from 2018 TLM</a>	Jordan Feld

<a href="#">Translating AASLD data to local practice</a>	Dinç Dinçer
<a href="#">HCV Elimination Strategies</a>	Ramazan Idilman
<a href="#">HCV and Liver Transplantation</a>	Ahmet Gurakar
<b>Session 6 Non-alcoholic Fatty Liver Disease</b>	
<a href="#">AASLD Guidelines</a>	Jasmohan Bajaj
<a href="#">Debrief from 2018 TLM</a>	Kymerly Watt
<a href="#">Translating AASLD data to local practice</a>	Yusuf Yılmaz
<a href="#">HCV and NAFLD Case Presentations, Q&amp;A and Panel Discussion</a>	Ebubekir Şenates, Enver Üçbilek, Murat Kıyıcı
<b>Session 7 Innovations in Immuno-Oncology</b>	
<a href="#">Burden of unresectable HCC</a>	Nurdan Tozun
<a href="#">First line HCC treatment</a>	Kymerly Watt
<a href="#">Tyrosine Kinase Inhibitors</a>	Paul Kwo
<a href="#">Immunotherapy: From checkpoint blockade to potential of cellular therapy</a>	W. Ray Kim
<b>Session 8 Hepatobiliary Malignancies</b>	
<a href="#">AASLD Guidelines</a>	Julie Heimbach
<a href="#">Debrief from 2018 TLM</a>	Paul Kwo
<a href="#">Translating AASLD data to local practice</a>	Müjdat Zeybel
<a href="#">HCC in NAFLD: Is surveillance possible?</a>	Kymerly Watt
<a href="#">HCC Case Presentations, Q&amp;A and Panel Discussion</a>	Levent Doğanay, Murat Harputluoğlu, Yücel Üstündağ